#Israel #Cancer Immunotherapy #Compugen #Holon #computational research

Compugen to Present at Oppenheimer Conference

Compugen Ltd., a pioneering company in the field of cancer immunotherapy and computational target discovery, is gearing up to participate in the 35th Annual Healthcare Life Sciences Conference hosted by Oppenheimer. This event is scheduled to take place virtually on February 11, 2025, at 8 AM ET, providing a platform for Compugen's management to engage in a fireside chat.

About the Event

The conference will be streamed live, enabling attendees to witness the developments and insights from Compugen's leadership. Those interested can access the live webcast through the Investor Relations section on Compugen's official website, with an opportunity to replay the session afterwards.

Compugen's Mission and Innovations

Compugen, a clinical-stage therapeutic discovery and development company, focuses on creating innovative therapeutic solutions for cancer treatment. The company's ground-breaking predictive computational discovery platform, known as Unigen™, plays a crucial role in identifying novel drug targets and biological pathways essential for developing effective cancer immunotherapies.

Currently, Compugen has several product candidates in different stages of development. Among them are:

• - COM701: A potential first-in-class anti-PVRIG antibody currently in Phase 1 trials.
• - COM902: A promising candidate aimed at targeting TIGIT, also in Phase 1 development.
• - Rilvegostomig: A bispecific antibody that targets PD-1 and TIGIT, presently in Phase 3 development through a collaboration with AstraZeneca.
• - COM503: This high affinity anti-IL-18 binding protein antibody is also in Phase 1 studies and is licensed to Gilead.

In addition to these leading candidates, Compugen is building a robust pipeline of early-stage immuno-oncology programs aimed at addressing various immune resistance mechanisms, showcasing their commitment to innovation in cancer therapy.

Future Directions

Compugen remains at the forefront of immunotherapy research, continuously exploring new targets and pathways to improve patient outcomes. With its headquarters in Israel and additional offices in San Francisco, CA, Compugen symbolizes a global effort in combating cancer through innovative science and technology.

Investors and stakeholders are encouraged to tune into the Oppenheimer Conference to gain firsthand knowledge about Compugen's advancements and future strategies for tackling cancer with cutting-edge therapies.

For further inquiries, Dr. Yvonne Naughton, Vice President and Head of Investor Relations and Corporate Communications at Compugen, is available for contact via email or phone.

The commitment of Compugen to enhance cancer treatment through computational insights makes this presentation a significant event for those invested in the healthcare and biotechnology sectors.